A phase 3 randomized, active-controlled, open-label, multicenter study to compare the efficacy and safety of MT-2870 monotherapy versus treatment of physician’s choice as second-line treatment for participant with recurrent or metastatic cervical cancer (TroFuse-020/GOG-3101/ENGOT-cx20).
Principal investigator: Heini Lassus
HUS, Helsinki University Hospital, Comprehensive Cancer Center
